| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fusion Proteins, bcr-abl | 25 | 2012 | 430 | 2.180 |
Why?
|
| Janus Kinase 2 | 10 | 2021 | 561 | 1.700 |
Why?
|
| Protein-Tyrosine Kinases | 20 | 2014 | 2428 | 1.400 |
Why?
|
| Cell Transformation, Neoplastic | 22 | 2011 | 2846 | 1.240 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 12 | 2020 | 494 | 1.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1760 | 0.980 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 14 | 2020 | 120 | 0.960 |
Why?
|
| Leukemia, Myeloid | 5 | 2020 | 693 | 0.940 |
Why?
|
| Piperazines | 17 | 2021 | 2552 | 0.900 |
Why?
|
| Myeloproliferative Disorders | 5 | 2021 | 616 | 0.860 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2022 | 5694 | 0.860 |
Why?
|
| Proto-Oncogene Proteins c-met | 8 | 2020 | 563 | 0.850 |
Why?
|
| Antineoplastic Agents | 23 | 2022 | 13658 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 20 | 2008 | 4525 | 0.800 |
Why?
|
| Adaptor Proteins, Signal Transducing | 15 | 2014 | 2906 | 0.750 |
Why?
|
| Leukemia, Myeloid, Acute | 15 | 2022 | 3626 | 0.740 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 12 | 2007 | 686 | 0.720 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 168 | 0.690 |
Why?
|
| Signal Transduction | 44 | 2021 | 23640 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5394 | 0.680 |
Why?
|
| Lung Neoplasms | 17 | 2023 | 13500 | 0.680 |
Why?
|
| Phosphoproteins | 15 | 2014 | 2450 | 0.660 |
Why?
|
| Up-Regulation | 6 | 2021 | 4146 | 0.660 |
Why?
|
| Point Mutation | 3 | 2011 | 1594 | 0.620 |
Why?
|
| Reactive Oxygen Species | 9 | 2012 | 2149 | 0.550 |
Why?
|
| Genes, abl | 5 | 2007 | 69 | 0.510 |
Why?
|
| Ubiquitin-Protein Ligases | 9 | 2002 | 1901 | 0.500 |
Why?
|
| Glycogen Synthase | 1 | 2015 | 62 | 0.490 |
Why?
|
| Pyrimidines | 16 | 2014 | 3046 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2024 | 8637 | 0.480 |
Why?
|
| Mesothelioma | 3 | 2020 | 774 | 0.480 |
Why?
|
| Exons | 3 | 2020 | 2393 | 0.480 |
Why?
|
| Staurosporine | 8 | 2020 | 241 | 0.470 |
Why?
|
| Oncogenes | 7 | 2013 | 1232 | 0.470 |
Why?
|
| Glycogen | 1 | 2015 | 252 | 0.460 |
Why?
|
| Mutation | 21 | 2023 | 30214 | 0.450 |
Why?
|
| Nuclear Proteins | 14 | 2022 | 5799 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2023 | 5335 | 0.440 |
Why?
|
| Phenylurea Compounds | 5 | 2020 | 531 | 0.440 |
Why?
|
| src Homology Domains | 7 | 2003 | 361 | 0.440 |
Why?
|
| Cell Movement | 16 | 2020 | 5209 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2024 | 998 | 0.420 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 1997 | 0.410 |
Why?
|
| Phosphatidylinositol 3-Kinases | 12 | 2009 | 2884 | 0.410 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 472 | 0.390 |
Why?
|
| Fructose-Bisphosphatase | 1 | 2011 | 25 | 0.390 |
Why?
|
| Multiple Myeloma | 15 | 2024 | 5197 | 0.390 |
Why?
|
| Cell Cycle | 8 | 2014 | 2932 | 0.390 |
Why?
|
| Phosphofructokinase-2 | 1 | 2011 | 33 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-kit | 5 | 2019 | 723 | 0.380 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 1997 | 434 | 0.380 |
Why?
|
| Cell Line, Tumor | 28 | 2024 | 17128 | 0.380 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 593 | 0.380 |
Why?
|
| Tyrosine | 12 | 2011 | 1427 | 0.370 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2012 | 101 | 0.370 |
Why?
|
| STAT5 Transcription Factor | 7 | 2012 | 268 | 0.370 |
Why?
|
| Apoptosis | 18 | 2021 | 9521 | 0.360 |
Why?
|
| Hematologic Neoplasms | 5 | 2019 | 1907 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2008 | 31 | 0.350 |
Why?
|
| Niacinamide | 1 | 2012 | 418 | 0.350 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2024 | 3409 | 0.350 |
Why?
|
| Phosphorylation | 23 | 2021 | 8314 | 0.340 |
Why?
|
| Small Molecule Libraries | 4 | 2021 | 742 | 0.320 |
Why?
|
| Cell Proliferation | 15 | 2021 | 10471 | 0.320 |
Why?
|
| Phosphoric Monoester Hydrolases | 3 | 2000 | 414 | 0.320 |
Why?
|
| Benzamides | 11 | 2007 | 1377 | 0.320 |
Why?
|
| Mice | 48 | 2024 | 82024 | 0.310 |
Why?
|
| Myeloid Cells | 2 | 2010 | 839 | 0.310 |
Why?
|
| Pyrazoles | 4 | 2021 | 2028 | 0.300 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1999 | 98 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 19 | 2021 | 6119 | 0.290 |
Why?
|
| Animals | 65 | 2024 | 169225 | 0.290 |
Why?
|
| Cell Adhesion | 11 | 2020 | 3096 | 0.280 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 707 | 0.280 |
Why?
|
| Cytoskeleton | 5 | 2003 | 1179 | 0.280 |
Why?
|
| Transcription Factors | 6 | 2024 | 12165 | 0.270 |
Why?
|
| Polycythemia Vera | 3 | 2012 | 160 | 0.270 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2007 | 176 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 4 | 2003 | 419 | 0.270 |
Why?
|
| Oncogene Proteins | 2 | 2008 | 717 | 0.270 |
Why?
|
| Imidazoles | 1 | 2012 | 1168 | 0.270 |
Why?
|
| Cell Survival | 7 | 2017 | 5772 | 0.260 |
Why?
|
| Cytoskeletal Proteins | 8 | 2003 | 1327 | 0.260 |
Why?
|
| Thrombopoietin | 3 | 1999 | 225 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2024 | 3609 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2953 | 0.250 |
Why?
|
| Mutagenesis | 2 | 2009 | 1228 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 11874 | 0.250 |
Why?
|
| Neoplasm Proteins | 6 | 2012 | 3601 | 0.250 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 456 | 0.250 |
Why?
|
| Metabolomics | 1 | 2015 | 1674 | 0.250 |
Why?
|
| Sulfonamides | 4 | 2021 | 1982 | 0.250 |
Why?
|
| Pyrazines | 6 | 2021 | 1205 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 9253 | 0.240 |
Why?
|
| Thrombocythemia, Essential | 1 | 2006 | 114 | 0.230 |
Why?
|
| Humans | 112 | 2024 | 767998 | 0.230 |
Why?
|
| Microscopy, Video | 4 | 2003 | 241 | 0.230 |
Why?
|
| Neoplasms | 5 | 2022 | 22369 | 0.230 |
Why?
|
| Enzyme Inhibitors | 8 | 2011 | 3726 | 0.230 |
Why?
|
| Mutation, Missense | 3 | 2010 | 2592 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2024 | 287 | 0.220 |
Why?
|
| DNA Mutational Analysis | 5 | 2010 | 4114 | 0.220 |
Why?
|
| Cell Line | 16 | 2010 | 15597 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-abl | 3 | 2014 | 145 | 0.220 |
Why?
|
| Drug Delivery Systems | 4 | 2013 | 2230 | 0.210 |
Why?
|
| Cell Line, Transformed | 8 | 2003 | 866 | 0.210 |
Why?
|
| Pyrimidinones | 3 | 2021 | 386 | 0.200 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2002 | 74 | 0.200 |
Why?
|
| Leukemia, Lymphoid | 1 | 2002 | 311 | 0.200 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 152 | 0.190 |
Why?
|
| Drug Repositioning | 2 | 2022 | 246 | 0.190 |
Why?
|
| Megakaryocytes | 4 | 2000 | 570 | 0.190 |
Why?
|
| Drugs, Investigational | 1 | 2004 | 211 | 0.190 |
Why?
|
| Antiviral Agents | 4 | 2023 | 3073 | 0.190 |
Why?
|
| Janus Kinases | 2 | 2013 | 253 | 0.190 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 1743 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 2931 | 0.190 |
Why?
|
| K562 Cells | 3 | 2009 | 644 | 0.180 |
Why?
|
| Aniline Compounds | 3 | 2021 | 1094 | 0.180 |
Why?
|
| Cell Adhesion Molecules | 4 | 2000 | 1613 | 0.180 |
Why?
|
| Cross Reactions | 1 | 2022 | 828 | 0.180 |
Why?
|
| Stem Cell Factor | 2 | 1999 | 194 | 0.170 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 662 | 0.170 |
Why?
|
| Enzyme Activation | 7 | 2013 | 3587 | 0.170 |
Why?
|
| Protein Structure, Tertiary | 5 | 2011 | 3771 | 0.170 |
Why?
|
| Interleukin-3 | 2 | 1999 | 425 | 0.170 |
Why?
|
| DNA Repair | 1 | 2009 | 2050 | 0.170 |
Why?
|
| Paxillin | 7 | 2008 | 86 | 0.170 |
Why?
|
| Estradiol | 3 | 2003 | 1951 | 0.160 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 110 | 0.160 |
Why?
|
| Protein Phosphatase 2 | 1 | 2021 | 231 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2000 | 457 | 0.160 |
Why?
|
| Histones | 1 | 2009 | 2600 | 0.160 |
Why?
|
| Erythropoietin | 2 | 2008 | 718 | 0.160 |
Why?
|
| Milk Proteins | 2 | 2000 | 161 | 0.160 |
Why?
|
| Genomic Instability | 2 | 2014 | 716 | 0.160 |
Why?
|
| Cell Division | 9 | 2004 | 4473 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 1605 | 0.150 |
Why?
|
| Stromal Cells | 4 | 2013 | 1336 | 0.150 |
Why?
|
| Mice, SCID | 5 | 2021 | 2627 | 0.140 |
Why?
|
| Proteins | 5 | 2004 | 6009 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2004 | 1610 | 0.140 |
Why?
|
| Mutant Proteins | 1 | 2019 | 488 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 3443 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2015 | 2456 | 0.140 |
Why?
|
| Receptors, Erythropoietin | 2 | 2008 | 144 | 0.140 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 1168 | 0.130 |
Why?
|
| Carrier Proteins | 2 | 2002 | 4937 | 0.130 |
Why?
|
| Indoles | 2 | 2009 | 1835 | 0.130 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 3428 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 454 | 0.130 |
Why?
|
| Benzothiazoles | 4 | 2020 | 248 | 0.130 |
Why?
|
| Polyenes | 2 | 1992 | 68 | 0.130 |
Why?
|
| Drug Design | 1 | 2021 | 1045 | 0.130 |
Why?
|
| Fractals | 1 | 2016 | 127 | 0.120 |
Why?
|
| Cell Lineage | 1 | 2024 | 2574 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2019 | 719 | 0.120 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 324 | 0.120 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 17617 | 0.120 |
Why?
|
| Hematopoiesis | 2 | 2024 | 2059 | 0.120 |
Why?
|
| Base Sequence | 5 | 2014 | 12417 | 0.120 |
Why?
|
| Glycolysis | 2 | 2016 | 837 | 0.110 |
Why?
|
| Drug Synergism | 4 | 2020 | 1760 | 0.110 |
Why?
|
| Stem Cells | 1 | 2007 | 3537 | 0.110 |
Why?
|
| Glucose | 3 | 2011 | 4351 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 354 | 0.110 |
Why?
|
| Receptors, Cytokine | 2 | 2009 | 258 | 0.110 |
Why?
|
| Thiophenes | 1 | 2017 | 570 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 361 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 4050 | 0.100 |
Why?
|
| Hydrogen Peroxide | 3 | 2002 | 740 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3115 | 0.100 |
Why?
|
| Bone Marrow | 3 | 2021 | 2935 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3238 | 0.100 |
Why?
|
| Tacrolimus | 3 | 1992 | 751 | 0.100 |
Why?
|
| Electron Transport Complex III | 1 | 2012 | 31 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2824 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 384 | 0.100 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2012 | 37 | 0.100 |
Why?
|
| Superoxides | 2 | 2003 | 389 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 4904 | 0.100 |
Why?
|
| Leukemia | 2 | 2015 | 1519 | 0.100 |
Why?
|
| Aconitate Hydratase | 1 | 2011 | 17 | 0.100 |
Why?
|
| Genes, ras | 1 | 2014 | 657 | 0.100 |
Why?
|
| Phosphotyrosine | 4 | 2004 | 458 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2000 | 1889 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 525 | 0.090 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2012 | 163 | 0.090 |
Why?
|
| B-Lymphocytes | 4 | 2003 | 4791 | 0.090 |
Why?
|
| Oxidation-Reduction | 2 | 2008 | 2227 | 0.090 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 186 | 0.090 |
Why?
|
| Hydroquinones | 2 | 2009 | 34 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 4576 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2022 | 2341 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 5 | 2021 | 2630 | 0.090 |
Why?
|
| Philadelphia Chromosome | 2 | 2001 | 119 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1992 | 423 | 0.080 |
Why?
|
| Adamantane | 2 | 2009 | 148 | 0.080 |
Why?
|
| Skin Aging | 1 | 2011 | 140 | 0.080 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 1837 | 0.080 |
Why?
|
| NADP | 1 | 2010 | 229 | 0.080 |
Why?
|
| Vanadates | 2 | 2000 | 82 | 0.080 |
Why?
|
| Transfection | 7 | 2007 | 5757 | 0.080 |
Why?
|
| Integrins | 3 | 2000 | 842 | 0.080 |
Why?
|
| Endothelial Growth Factors | 2 | 2001 | 671 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2021 | 3514 | 0.080 |
Why?
|
| ras Proteins | 2 | 2009 | 1054 | 0.080 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 1418 | 0.080 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 2415 | 0.080 |
Why?
|
| Boronic Acids | 3 | 2014 | 915 | 0.080 |
Why?
|
| Blotting, Western | 6 | 2014 | 5023 | 0.080 |
Why?
|
| Benzimidazoles | 3 | 2020 | 863 | 0.080 |
Why?
|
| Lymphokines | 2 | 2001 | 924 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2021 | 3228 | 0.080 |
Why?
|
| Chemotaxis | 2 | 2003 | 600 | 0.080 |
Why?
|
| Biological Products | 1 | 2017 | 948 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2000 | 9614 | 0.080 |
Why?
|
| Cross-Linking Reagents | 1 | 2011 | 693 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2024 | 11666 | 0.070 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2008 | 53 | 0.070 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 230 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2011 | 618 | 0.070 |
Why?
|
| Mitochondria | 2 | 2016 | 3681 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2009 | 3140 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2011 | 691 | 0.070 |
Why?
|
| DNA, Single-Stranded | 1 | 2009 | 351 | 0.070 |
Why?
|
| Cytokines | 4 | 2009 | 7453 | 0.070 |
Why?
|
| DNA Damage | 2 | 2014 | 2470 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2015 | 12797 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2015 | 5904 | 0.070 |
Why?
|
| Precipitin Tests | 3 | 2002 | 816 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2009 | 2936 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2018 | 464 | 0.070 |
Why?
|
| Cyclin D2 | 1 | 2006 | 97 | 0.070 |
Why?
|
| Nitriles | 1 | 2011 | 980 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 948 | 0.060 |
Why?
|
| Recombinant Proteins | 6 | 2004 | 6515 | 0.060 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2008 | 381 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 942 | 0.060 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4289 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 268 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2020 | 1966 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 627 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 317 | 0.060 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 2601 | 0.060 |
Why?
|
| Phloretin | 1 | 2004 | 16 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 1972 | 0.060 |
Why?
|
| Half-Life | 2 | 2011 | 651 | 0.060 |
Why?
|
| Immunosuppressive Agents | 3 | 1992 | 4210 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 899 | 0.060 |
Why?
|
| S Phase | 1 | 2006 | 424 | 0.060 |
Why?
|
| G1 Phase | 1 | 2006 | 403 | 0.060 |
Why?
|
| Caveolins | 1 | 2004 | 102 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 1492 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2021 | 1942 | 0.060 |
Why?
|
| Cell Size | 2 | 2003 | 626 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1351 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2015 | 7876 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2004 | 333 | 0.060 |
Why?
|
| Caspases | 1 | 2007 | 882 | 0.060 |
Why?
|
| Cyclins | 1 | 2006 | 605 | 0.060 |
Why?
|
| RNA Interference | 3 | 2022 | 2830 | 0.060 |
Why?
|
| Pandemics | 2 | 2020 | 8750 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 662 | 0.050 |
Why?
|
| Female | 13 | 2021 | 397102 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2004 | 740 | 0.050 |
Why?
|
| GATA1 Transcription Factor | 1 | 2024 | 306 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 12827 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 437 | 0.050 |
Why?
|
| Caveolae | 1 | 2002 | 54 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2001 | 1608 | 0.050 |
Why?
|
| Oncogene Protein v-cbl | 1 | 2002 | 11 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 658 | 0.050 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2002 | 101 | 0.050 |
Why?
|
| Kinetics | 4 | 1999 | 6328 | 0.050 |
Why?
|
| Prognosis | 4 | 2021 | 29984 | 0.050 |
Why?
|
| Acetylcysteine | 2 | 2003 | 262 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1369 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2002 | 91 | 0.050 |
Why?
|
| Chemokines, CXC | 2 | 2002 | 420 | 0.050 |
Why?
|
| Microsomes, Liver | 2 | 1992 | 174 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2021 | 25 | 0.050 |
Why?
|
| Erythroid Precursor Cells | 1 | 2002 | 211 | 0.050 |
Why?
|
| Guanosine Triphosphate | 1 | 2002 | 315 | 0.050 |
Why?
|
| Helminth Proteins | 1 | 2002 | 173 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2012 | 3740 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2020 | 1008 | 0.050 |
Why?
|
| Protein Binding | 5 | 2002 | 9343 | 0.050 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2000 | 19 | 0.050 |
Why?
|
| Piperidines | 2 | 2020 | 1667 | 0.050 |
Why?
|
| Pyrroles | 2 | 2019 | 1123 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2003 | 475 | 0.040 |
Why?
|
| Growth Substances | 1 | 2003 | 759 | 0.040 |
Why?
|
| Rotenone | 1 | 2000 | 50 | 0.040 |
Why?
|
| Pyridones | 1 | 2006 | 819 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2011 | 4176 | 0.040 |
Why?
|
| Thiazoles | 3 | 2012 | 1542 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 2001 | 1207 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-crk | 2 | 1997 | 13 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 8052 | 0.040 |
Why?
|
| Drug Resistance | 2 | 2003 | 1598 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 21209 | 0.040 |
Why?
|
| Injections | 1 | 2003 | 840 | 0.040 |
Why?
|
| Thiocarbamates | 1 | 1999 | 30 | 0.040 |
Why?
|
| Binding Sites | 4 | 2003 | 6022 | 0.040 |
Why?
|
| Mercaptoethanol | 1 | 1999 | 61 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10757 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 10264 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 2473 | 0.040 |
Why?
|
| Tubulin | 1 | 2003 | 694 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 13420 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 375 | 0.040 |
Why?
|
| Genes, fos | 1 | 1999 | 176 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2002 | 1647 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 381 | 0.040 |
Why?
|
| Protein Transport | 2 | 2001 | 1951 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 874 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1059 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 1047 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2003 | 1621 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2000 | 2857 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2011 | 3589 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2003 | 751 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2002 | 729 | 0.040 |
Why?
|
| DNA Primers | 2 | 2014 | 2827 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 521 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1997 | 121 | 0.040 |
Why?
|
| Telomerase | 1 | 2003 | 751 | 0.040 |
Why?
|
| Microscopy | 1 | 2003 | 908 | 0.040 |
Why?
|
| Streptomyces | 1 | 2017 | 91 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 1405 | 0.040 |
Why?
|
| Triazines | 1 | 2019 | 311 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2008 | 2908 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 930 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 1999 | 340 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2001 | 1688 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22286 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 11068 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2018 | 412 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1997 | 224 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2017 | 1230 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2014 | 635 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8536 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 582 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 1777 | 0.030 |
Why?
|
| Crk-Associated Substrate Protein | 3 | 2004 | 39 | 0.030 |
Why?
|
| Talin | 1 | 1996 | 47 | 0.030 |
Why?
|
| Retinoblastoma-Like Protein p130 | 3 | 2004 | 72 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 2889 | 0.030 |
Why?
|
| TYK2 Kinase | 1 | 1995 | 38 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1996 | 228 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 892 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2004 | 2061 | 0.030 |
Why?
|
| Antioxidants | 2 | 2003 | 1674 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 1995 | 108 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1667 | 0.030 |
Why?
|
| Mitochondrial Proteins | 2 | 2016 | 979 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1995 | 159 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 534 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 1995 | 343 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 705 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 2748 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1997 | 547 | 0.030 |
Why?
|
| Fibronectins | 2 | 2011 | 722 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 1997 | 1391 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2819 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 1883 | 0.030 |
Why?
|
| Norpregnenes | 1 | 1992 | 6 | 0.030 |
Why?
|
| Models, Biological | 2 | 2001 | 9493 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 433 | 0.030 |
Why?
|
| Biotransformation | 1 | 1992 | 166 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2017 | 843 | 0.030 |
Why?
|
| Male | 8 | 2013 | 364638 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 2088 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 7575 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 3055 | 0.020 |
Why?
|
| Methacrylates | 1 | 2012 | 110 | 0.020 |
Why?
|
| Catalase | 1 | 2012 | 215 | 0.020 |
Why?
|
| Rats | 5 | 2011 | 23751 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2013 | 5402 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2011 | 219 | 0.020 |
Why?
|
| Electron Transport | 1 | 2012 | 211 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 1995 | 874 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 297 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3814 | 0.020 |
Why?
|
| Drug Approval | 1 | 2017 | 820 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2020 | 19015 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2981 | 0.020 |
Why?
|
| Gene Expression | 3 | 2015 | 7597 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2001 | 748 | 0.020 |
Why?
|
| Cisplatin | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Dermis | 1 | 2011 | 203 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 22381 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 596 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 686 | 0.020 |
Why?
|
| Chemokine CXCL12 | 2 | 2002 | 457 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2011 | 943 | 0.020 |
Why?
|
| Semaphorins | 1 | 2009 | 96 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1991 | 778 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 304 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 411 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 757 | 0.020 |
Why?
|
| src-Family Kinases | 2 | 2004 | 539 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3912 | 0.020 |
Why?
|
| Sirolimus | 2 | 1992 | 1539 | 0.020 |
Why?
|
| Metformin | 1 | 2016 | 909 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2013 | 1194 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1996 | 2614 | 0.020 |
Why?
|
| Dexamethasone | 2 | 2007 | 1964 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 663 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 161 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 1560 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2002 | 14484 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 1683 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1995 | 2881 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 1999 | 1084 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 9016 | 0.020 |
Why?
|
| Cell Communication | 1 | 2013 | 1660 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 3956 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6225 | 0.020 |
Why?
|
| Melphalan | 1 | 2007 | 421 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 1765 | 0.020 |
Why?
|
| Indazoles | 1 | 2006 | 306 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2014 | 3402 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2004 | 46 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 18345 | 0.010 |
Why?
|
| Microarray Analysis | 1 | 2006 | 753 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2003 | 123 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 4573 | 0.010 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2003 | 105 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2008 | 1211 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 255 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 10396 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2009 | 3620 | 0.010 |
Why?
|
| Chromones | 1 | 2002 | 148 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2002 | 103 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2001 | 113 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1992 | 8120 | 0.010 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2001 | 46 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 59600 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 526 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5151 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 205 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2003 | 738 | 0.010 |
Why?
|
| Exocytosis | 1 | 2001 | 323 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 1091 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6070 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2001 | 252 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2001 | 330 | 0.010 |
Why?
|
| Actins | 2 | 1997 | 2064 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3618 | 0.010 |
Why?
|
| Morpholines | 1 | 2002 | 584 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2000 | 250 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2055 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2000 | 284 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1715 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 1104 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 560 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 3951 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 447 | 0.010 |
Why?
|
| Cytarabine | 1 | 2000 | 695 | 0.010 |
Why?
|
| Doxycycline | 1 | 2000 | 348 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2000 | 7469 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 1533 | 0.010 |
Why?
|
| Son of Sevenless Proteins | 1 | 1997 | 27 | 0.010 |
Why?
|
| Genes, src | 1 | 1997 | 51 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 832 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 1996 | 87 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 1997 | 120 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 1989 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 1244 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 1997 | 193 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1997 | 183 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2000 | 646 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1526 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 7613 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2003 | 2201 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1997 | 657 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 1550 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1997 | 1065 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 13042 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13667 | 0.010 |
Why?
|
| Blood Cells | 1 | 1996 | 309 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 1731 | 0.010 |
Why?
|
| Aged | 2 | 2021 | 171453 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2914 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 65360 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1996 | 1435 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1997 | 5505 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1997 | 910 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1996 | 671 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 11930 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 4427 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2001 | 3657 | 0.010 |
Why?
|
| Methylcholanthrene | 1 | 1991 | 30 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 223422 | 0.010 |
Why?
|
| Phenobarbital | 1 | 1991 | 192 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 26418 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 2087 | 0.010 |
Why?
|
| Temperature | 1 | 1997 | 2234 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 4938 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1997 | 1739 | 0.010 |
Why?
|
| Time Factors | 2 | 2001 | 40210 | 0.000 |
Why?
|
| Promoter Regions, Genetic | 1 | 2000 | 5798 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1991 | 1419 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1997 | 4035 | 0.000 |
Why?
|
| Child | 1 | 2009 | 80905 | 0.000 |
Why?
|
| Adult | 1 | 2009 | 223577 | 0.000 |
Why?
|